Yoshifumi Soejima

589 total citations
27 papers, 440 citations indexed

About

Yoshifumi Soejima is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yoshifumi Soejima has authored 27 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Yoshifumi Soejima's work include Lung Cancer Research Studies (12 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer therapeutics and mechanisms (6 papers). Yoshifumi Soejima is often cited by papers focused on Lung Cancer Research Studies (12 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer therapeutics and mechanisms (6 papers). Yoshifumi Soejima collaborates with scholars based in Japan, United States and United Kingdom. Yoshifumi Soejima's co-authors include Masaaki Fukuda, Akihito Kubo, Yoshio Okano, Masahiko Ando, Atsuhisa Tamura, Tomoya Kawaguchi, Kazuhiro Sakamoto, Kazuhiro Asami, Yoshio Tomizawa and Minoru Takada and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology and Respiratory Medicine.

In The Last Decade

Yoshifumi Soejima

25 papers receiving 428 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yoshifumi Soejima Japan 8 309 269 95 50 43 27 440
Enzo Veltri Italy 10 353 1.1× 150 0.6× 71 0.7× 57 1.1× 42 1.0× 13 421
Yukihiro Yano Japan 13 253 0.8× 270 1.0× 98 1.0× 59 1.2× 62 1.4× 48 546
Pranshu Bansal United States 11 289 0.9× 218 0.8× 121 1.3× 34 0.7× 50 1.2× 21 510
Robert L. Ruxer United States 10 178 0.6× 129 0.5× 162 1.7× 27 0.5× 23 0.5× 13 352
Frédéric Vallot Belgium 7 359 1.2× 268 1.0× 251 2.6× 62 1.2× 59 1.4× 18 613
K. Komuta Japan 9 287 0.9× 225 0.8× 97 1.0× 148 3.0× 34 0.8× 19 579
Fernando Gaion Italy 8 411 1.3× 143 0.5× 199 2.1× 20 0.4× 74 1.7× 11 541
Nathalie Letarte Canada 10 221 0.7× 141 0.5× 137 1.4× 33 0.7× 46 1.1× 26 477
Hiroshi Takatani Japan 15 382 1.2× 196 0.7× 264 2.8× 111 2.2× 63 1.5× 42 559
Maria Taboada United Kingdom 11 510 1.7× 524 1.9× 62 0.7× 44 0.9× 64 1.5× 16 855

Countries citing papers authored by Yoshifumi Soejima

Since Specialization
Citations

This map shows the geographic impact of Yoshifumi Soejima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshifumi Soejima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshifumi Soejima more than expected).

Fields of papers citing papers by Yoshifumi Soejima

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshifumi Soejima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshifumi Soejima. The network helps show where Yoshifumi Soejima may publish in the future.

Co-authorship network of co-authors of Yoshifumi Soejima

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshifumi Soejima. A scholar is included among the top collaborators of Yoshifumi Soejima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshifumi Soejima. Yoshifumi Soejima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kawaguchi, Tomoya, Masahiko Ando, Kazuhiro Asami, et al.. (2014). Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). Journal of Clinical Oncology. 32(18). 1902–1908. 197 indexed citations
2.
3.
4.
Fukuda, Minoru, Yoichi Nakamura, Akitoshi Kinoshita, et al.. (2012). Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer. Cancer Chemotherapy and Pharmacology. 70(5). 645–651. 9 indexed citations
5.
Sawai, Toyomitsu, et al.. (2011). A Case of <i>Mycobacterium intracellulare </i>Pulmonary Infection with Vertebral Osteomyelitis. Kansenshogaku zasshi. 85(5). 527–531. 4 indexed citations
6.
Soejima, Yoshifumi, et al.. (2010). A case of Serratia granuloma in the soft tissue around the left kidney: a role of PTHrP in the formation of Serratia granuloma. Journal of Infection and Chemotherapy. 16(2). 126–130. 2 indexed citations
7.
Nakamura, Yoichi, Hiroshi Soda, Mikio Oka, et al.. (2010). Randomized Phase II Trial of Irinotecan with Paclitaxel or Gemcitabine for Non-small Cell Lung Cancer: Association of UGT1A1*6 and UGT1A1*27 with Severe Neutropenia. Journal of Thoracic Oncology. 6(1). 121–127. 27 indexed citations
8.
Nakamura, Shigeki, Katsunori Yanagihara, Tomo Mihara, et al.. (2008). [Clinical characteristics of pneumonia in the oldest old patients].. PubMed. 46(9). 687–92. 1 indexed citations
9.
Takatani, Hiroshi, Hiroshi Soda, Yoichi Nakamura, et al.. (2007). Phase I Study of Irinotecan and Gemcitabine in Previously Untreated Patients with Advanced Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology. 37(5). 353–357. 5 indexed citations
10.
Nakamura, Shigeki, Katsunori Yanagihara, Koichi Izumikawa, et al.. (2007). Leukocytoclastic Vasculitis after Pneumococcal pneumonia in an Elderly Adult. Internal Medicine. 46(8). 487–490.
11.
Fukuda, Minoru, Hiroshi Soda, Yoshifumi Soejima, et al.. (2006). A phase I trial of carboplatin and etoposide for elderly (≥75 year-old) patients with small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 58(5). 601–606. 6 indexed citations
12.
Nakamura, Shigeki, Tomo Mihara, Tsutomu Hitotsumatsu, et al.. (2006). Case Report of Disseminated Nocardiosis Complicated in an Elderly Person with Pneumoconiosis. Kansenshogaku zasshi. 80(6). 721–725. 4 indexed citations
13.
Fukuda, Minoru, Mikio Oka, Hiroshi Soda, et al.. (2004). Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 54(6). 573–577. 24 indexed citations
14.
Saeki, Sachiko, Hiroto Matsuse, Terufumi Shimoda, et al.. (2004). [A case of pulmonary Mycobacterium gordonae infection with pleural effusion].. PubMed. 42(1). 103–7. 3 indexed citations
15.
Saeki, Sachiko, Yoshifumi Soejima, Terufumi Shimoda, Hiroto Matsuse, & Shigeru Kohno. (2003). [A case of pulmonary involvement of malignant lymphoma with diffuse ground-glass opacity in chest CT].. PubMed. 41(1). 44–7. 3 indexed citations
16.
Saeki, Sho, et al.. (2003). Successful treatment of theophylline toxicity by upper gastrointestinal endoscopy. Respiratory Medicine. 97(6). 734–735. 7 indexed citations
17.
Yamaguchi, Tetsuji, et al.. (2000). Hepatic Artery Pseudoaneurysms in a Patient Treated for Miliary Tuberculosis.. Internal Medicine. 39(11). 994–998. 7 indexed citations
18.
Kojima, Akira, Yoshifumi Soejima, Hiroaki Okamoto, et al.. (1994). A Randomized Prospective Study of Imipenem-Cilastatin With or Without Amikacin as an Empirical Antibiotic Treatment for Febrile Neutropenic Patients. American Journal of Clinical Oncology. 17(5). 400–404. 20 indexed citations
19.
Jiao, Huaiyuan, et al.. (1992). Differential macrophage-mediated cytotoxicity to P388 leukemia cells and its drug-resistant cells examined by a new MTT assay. Leukemia Research. 16(12). 1175–1180. 6 indexed citations
20.
Soejima, Yoshifumi, et al.. (1962). [Chemical analysis of vernix caseosa].. PubMed. 37. 125–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Enzo Veltri Breakdown of academic impact, for papers by Yukihiro Yano Breakdown of academic impact, for papers by Pranshu Bansal Breakdown of academic impact, for papers by Robert L. Ruxer Breakdown of academic impact, for papers by Frédéric Vallot Breakdown of academic impact, for papers by K. Komuta Breakdown of academic impact, for papers by Fernando Gaion Breakdown of academic impact, for papers by Nathalie Letarte Breakdown of academic impact, for papers by Hiroshi Takatani Breakdown of academic impact, for papers by Maria Taboada
Rankless by CCL
2026